Alynn M Anzevino RPH

Recommended Articles

• Gum Disease is Common in Pot Smokers

  A new study published in, The Journal of American Medical Association, reports that pot use is associated with gum disease. This disease, considered to be a disease due to aging, was very common among people who smoke marijuana. The result remained the same even after accounting for all other...

• What is the Best Diet for Healthy Hair?

  One of the most important things to remember while choosing foods for healthy hair is that changes will be obvious only after some time. In the case of skin, change to a healthy lifestyle would be immediately reflected, while in the case of hair, one will have to wait for weeks and months to see the...

• Jerry Lewis Remembered for his Role in Muscular Dystrophy Fundraising

  Comedian and entertainer, Jerry Lewis, died Sunday, August 20, 2017 at age 91. And one of the things he will be most remembered for is his work with the Muscular Dystrophy Association. While more than $2.5 billion were raised from 1966 to 2010 through the annual telethons that Lewis hosted, some of...

• What Are the Common Lung Irritants Found at Home?

  Traffic exhaust or second hand smoke are sure to trigger a number of lung issues, particularly if you are susceptible to respiratory disorders. However, there are a number of very common, yet hidden, triggers in one's household that can lead to symptoms of asthma and other respiratory ailments.There...

• The Early Signs of Lupus

  Lupus is associated with a number of symptoms and conditions that can lead a person to seek help from a doctor. If you have recently been diagnosed with lupus, you may have experienced the following.Signs of LupusFatigue: Almost all people who have lupus would experience various levels of fatigue....

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...